Potential New Standard of Care in First-Line Cervical Cancer May Include Pembrolizumab Plus Chemotherapy Combo
September 18, 2021

Patients with cervical cancer receiving pembrolizumab plus chemotherapy with or without bevacizumab in the frontline setting had improvement in overall survival, potentially representing a new standard of care regimen.

Reduction In Disease Recurrence, Death With Adjuvant Pembrolizumab Noted in Resected High-Risk Stage II Melanoma
September 18, 2021

The use of adjuvant pembrolizumab resulted in a recurrence-free survival benefit for patients with resected high-risk stage II melanoma.

PFS Enhanced With Olaparib Rechallenge in Relapsed Ovarian Cancer After Prior PARP
September 18, 2021

Patients previously treated with PARP inhibitors showed an improvement in median progression-free survival when rechallenged with olaparib maintenance.